As a result, omacetaxine represses growth and increases apoptosis in HCC patient-derived organoids, blocking the formation of crucial oncoproteins such as MYC, β-catenin, cyclin D1, and MET [150]. The gene discussed is MET; the disease is hepatocellular carcinoma.